
Opinion|Videos|June 17, 2024
Adverse Effect Management and the Role of Immunotherapy in NMIBC
Experts on bladder cancer discusses strategies to minimize adverse effects and the role of immunotherapy in BCG-unresponsive NMIBC treatment paradigms.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Initial prostate cancer presentation, family history linked to survival in mCRPC
2
State of Men’s Health Act: What urologists need to know
3
FDA greenlights phase 1 trial of ADI-212 in mCRPC
4
Nicole L. Miller, MD, FACS, on persistent LUTS after BPH treatment
5













